Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

The epidermal growth factor receptor (EGFR, HER1) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). After initial promising results with EGFR‐targeted therapies such as cetuximab, therapeutic resistance has become a major clinical problem, and new treatment options are theref...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: De Pauw, Ines, Lardon, Filip, Van den Bossche, Jolien, Baysal, Hasan, Fransen, Erik, Deschoolmeester, Vanessa, Pauwels, Patrick, Peeters, Marc, Vermorken, Jan Baptist, Wouters, An
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983215/
https://ncbi.nlm.nih.gov/pubmed/29603584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12197
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados